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Introduction. A survey was sent to referring oncologists (ROs) to explore the reasons behind their referral patterns and perceptions
of Phase I studies before and after being provided with outcome data from advanced colorectal cancer (ACRC) patients who
participatedinPhaseItrialsattheRoyalMarsdenHospital(RMH).Results.Theresponseratewas32/50(64%).Themostcommon
reason for referral was exhaustion of standard treatments (31%), and the main reason for referring to the RMH was proximity to
patients (28%). The most frequent clinical parameter assessed prior to referral was performance status (93%). ROs spent a median
of 15min (range: 5–45min) discussing general aspects of Phase I trials. In the second part of the questionnaire, after reviewing
clinical outcome data of ACRC patients who participated in Phase I trials, 47% would change their approach, speciﬁcally, spend
more time to discuss risks and beneﬁts of Phase I trials (9%), consider prognostic factors before referral (13%), and increase the
number of referrals (25%). Conclusion. This is the ﬁrst report focusing on communication between ROs and a specialist Phase
I unit. Outcome reporting can improve communication with ROs and importantly has the potential for better patient selection
considered for Phase I oncology trials.
1.Introduction
The clinical outcome of Phase I trials is usually descriptive
due to small patient numbers. Still, there is evidence that
a signiﬁcant number of patients with ACRC derive clinical
beneﬁt, at least in the form of meaningful prolonged disease
stabilisation[1].Moreover,patientselectionbasedonclinical
parameterssuchasalbumin,LDH,andnumberofmetastatic
sites may be utilised to identify patients who may beneﬁt
from Phase I study treatment [2].
ThemotivationforpatientstoparticipateinPhaseItrials
is broad, ranging from personal beneﬁt to pure altruism
[3]. Unlike their treating oncologists, patients generally have
high expectations with regards to clinical beneﬁt and are
even willing to accept greater drug-related toxicities from
experimental therapy [4–6]. In this context patients rely
heavily on the opinion and expertise of their oncologists to
balance the risks and beneﬁts of Phase I trial treatment. Yet,
most general oncologists may often have limited experience
withPhaseItrialsofmodernagents.Itisthereforeimportant
to gain a better understanding of referral patterns of ROs as
wellastheirperceptionsofPhaseIclinicaltrials.Inthisstudy
a structured questionnaire was sent to all oncologists who
referred patients to the RMH for Phase I trials. The main
goalofthestudywastwofold:(a)improveourunderstanding
of the referral patterns of oncologists and (b) investigate
their general perception of experimental therapy and the
associated prognosis. Finally, we also aimed at obtaining
feedback on clinical outcome data for ACRC patients who
participated in Phase I trials and were part of a previous
outcome analysis. Brieﬂy, this analysis identiﬁed that a
considerable amount of patients had clinical beneﬁt, as
measured in prolonged stable disease (SD) [1]. Patients
with SD had generally a better RMH prognostic score and
achieved an OS of 40.6 weeks compared to 17.4 weeks for
patients with disease progression.2 Journal of Oncology
2. Methods
This study was carried out at the Royal Marsden Hospital,
Surrey, UK, and was reviewed and approved by the institu-
tion’s audit committee.
Two questionnaires were sent together (Figure 1): the
ﬁrst was designed to explore the perceptions of oncologists
about Phase I clinical trials. Questionnaire 1 (questions: 1–
5) included questions on the background of the referring
physicians, their clinical experience and familiarity with
general trial concepts, as well as on logistical issues involved
in Phase I trials. In addition, Questionnaire 1 (questions: 6–
15) evaluated the most common reasons for referral to Phase
I clinical trials, reasons for referral to the RMH, baseline
patient characteristics that were taken into account before
referring them for Phase I treatment, estimated progression-
freesurvival(PFS)andoverallsurvival(OS)forpatientswith
ACRC participating in Phase I trials, and variables that could
aﬀect the patients’ prognosis. The ﬁrst questionnaire had
to be ﬁlled prior to reviewing the clinical Phase I outcome
results for ACRC patients (summary of results shown in
Table 1).Followingthisparticipantswereinvitedtocomplete
questionnaire 2.
The second questionnaire (questions 16–21) assessed if
a better knowledge regarding clinical Phase I trial outcome
for ACRC patients would aﬀe c tr e f e r r a lt r e n d so fR O st o
Phase I trials and whether this would impact on their clinical
practice. Overall, a total of 21 questions were included in
both questionnaires, some being single and others multiple
choice questions. All four pages (invitation letter, Ques-
tionnaire 1, clinical outcome data, and Questionnaire 2)
were sent in the same envelope in this exact order with
an additional preposted envelope enclosed. The responses
to the Questionnaires were kept conﬁdential and contained
no identifying codes or tags, making it anonymous. For
this reason, a general reminder was sent in 3 weeks time.
At the end of Questionnaire 2 there was space for any
additional comments one should wish to make. Participants
were invited to give their names if they were interested in
getting feedback on the results of the survey.
All statistical analyses were performed using the SPSS
Software (Version 12.0; SPSS, Chicago, Ill, USA). Descriptive
statistics on survey questionnaire are presented, and total
percentages are shown.
3. Results
3.1. Questionnaire 1. Thirty-two out of 50 questionnaires
(64%) were returned from medical and clinical oncologists
(16 each). The median clinical experience in the ﬁeld of
oncology was 10yrs (range: 2–25). Sixty-six percent of the
oncologists had previous Phase I experience, and more
than 80% were familiar with logistics and general eligibility
criteria for Phase I trials.
The most common reason for referring patients for
participation in Phase I clinical trials was lack of treatment
options and beneﬁt development of new agents, see Table 2.
The discussion of Phase I trials was found to be initiated by
ROs in more than 50% of the cases and only in less than
10% of the cases by the patient. The reasons for referral
speciﬁcally to the RMH Drug Development Unit were
found to be the proximity to the patients’ home (28%), the
awareness of speciﬁc trials ongoing at the RMH unit (22%),
considering RMH a centre of excellence (22%), knowing a
consultant at the unit personally (13%), previously working
at RMH (9%), and patients’ request (3%).
The most common baseline characteristics of patients
that are taken into account before referral were performance
status (93%), life expectancy greater than 3 months (59%),
and normal renal function (56%) (see Table 3). The ability
to travel as well as time involvement was additional factors
which were added by the respondents and were not part of
the original options of the questionnaire.
ROs replied that they refer about 5% (range 0.5–20%) of
their ACRC patients for consideration of Phase I trials and
that they spend a median time of 15min (range: 5–60min)
to discuss Phase I trials. The main points discussed with
patients are the possibility of clinical beneﬁt and the aims
of Phase I trials (see Table 4). The oncologists estimated the
median PFS and OS of ACRC patients undergoing Phase I
trials to be 8 and 24 weeks, respectively. The most prominent
variables oncologists felt impact on clinical outcome were
low albumin, poor PS, and number of metastatic sites (see
Table 5).
3.2. Questionnaire 2. After completing Questionnaire 1 and
having read the results of our clinical audit (resume in
Table 1) ROs were asked to complete Questionnaire 2.
Overall 25/32 (78%) of the ROs stated that the clinical
outcome data for patients with ACRC in Phase I trials met
their expectations. Six out of the 32 (19%) ROs estimated
that patients would have a worse outcome and only 1 in
32 (3%) expected patients to have a better outcome if
they were not included in the trial. Importantly, 25% of
ROs felt that the clinical outcome results they just read
will impact on their future patient selection. Moreover, the
majority of oncologists (88%) replied that our questionnaire
in combination with the outcome data increased their
knowledge with regards to Phase I oncology trials, and 81%
of ROs declared their interest in being involved in similarly
structured surveys in the future. As a result of this survey,
9% of the oncologists would increasetheir time with patients
to discuss Phase I trial aspects and outcome, 13% said they
would include prognostic factors associated with survival
before referring patients, while 25% are planning to increase
their number of referrals.
4. Discussion
Patients who participate in Phase I trials have often high
expectations of deriving personal clinical beneﬁt despite the
fact that beneﬁt from Phase I trial participation is generally
limited [2, 6, 8]. Given their short life expectancy and lack
of realistic treatment options patients may be vulnerable.
One of the paramount roles for oncologists in this setting
is to advise patients in decision-making and also to balance
potential risks and beneﬁts of participating in Phase-I trials.Journal of Oncology 3
1. What is your specialty? 2. How many years have you worked as a specialist? ______ yrs
Medical Oncology 3. Do you have previous Phase I experience? Yes  No
Clinical Oncology Yes No
5. Are you familiar with the logistical issues involved in phase I? Yes No
No other options available Transfer the care
Possibility of clinical beneﬁt for patient Rather than having end stage disease discussion
Possibility of psychological beneﬁt for patient Know about a speciﬁc ongoing trial in the unit
Beneﬁt the development of new anticancer agents Other: _______________________________
Patients’ or families’ request
Yes No
8. If yes, what is the main reason?
Worked before or is working here  Know personally any consultant
Closest phase 1 unit to the patient Centre of excellence 
Patients’ request Other: _______________________________
Know about a speciﬁc ongoing trial in the unit
9. Do you or your patients usually suggest experimental treatment when standard therapy has failed?  
Patient Physician Both
Good performance status Age
Normal liver function  Prognosis > 3 months
Normal renal function Prognosis > 6 months
Normal full blood count Nothing, refer regardless
Good nutritional status Other:_______________________________
11.  How long do you generally spend with your patients to discuss experimental treatment?   __________ min
12.  What is the percentage of patients that you refer to phase 1 from your centre?   __________ %
13.  What do you usually spend more time discussing? (single choice)
Possibility of any clinical beneﬁt  Aims of phase 1 trials (dose ﬁnding/toxicity)
Speciﬁc chance of response to phase 1 trials Speciﬁc drugs that could potentially be of beneﬁt 
Chance of helping future cancer patients Other: ________________________________
Risk of side effects
14. What do you think is the median PFS/OS for patients with metastatic colorectal cancer that start phase 1 treatment?   
PFS   _______  months OS________ months
15. Which of these variables do you think can affect prognosis of patients? (please select more than one if applicable)
Age Lung metastases
Gender Number of metastatic sites
Lines of chemotherapy Albumin 
Previous biological agents LDH
Previous local procedures (liver resection, RFA) Haemoglobin
Performance status Other: __________________________________
Liver metastases
16. After reading the results of our audit, do the outcomes of Phase I trials in colorectal cancer meet your expectations?
Thought patients usually did better Thought patients usually fared worst About right; met my expectations
17. After reading the results of our audit, which do you think is the most important issue to discuss with patients?
Possibility of any clinical beneﬁt  Aims of phase 1 trials (dose ﬁnding/toxicity)
Speciﬁc chance of response to phase 1 trials Prognostic factors that can affect survival 
Chance of helping future cancer patients Other: __________________________________
18. Knowing the outcomes of the patients on phase I trials, how is this likely to change your clinical practice? 
No change to in my approach Increase number of referrals
Spend more time with patients to discuss
general aspects and outcome
Look out for prognostic factors that might affect survival 
Stop/cut down referring patients Other: __________________________________
19. Based on our results, would you be more selective when referring patients? Yes No
20. After reading our results and answering the questionnaire, has this increased your knowledge regarding phase 1 trials in 
ACRC?
Yes No
21. Would you be keen to answer future questionnaires like this? Yes No
4. Are you familiar with general phase I eligibility criteria?
7. Have you referred patients to the Drug Development Unit (Phase I) Royal Marsden Hospital?   
 
Questionnaire 1-Background experience
Questionnaire 1-Reasons for referral and general understanding
Questionnaire 2-Feedback after reading audit results
6. What are the most common reasons for your referral? (single choice)
10. Which baseline characteristics do you take into account before referring patients to phase 1 treatment? (please select more than one if applicable)
Figure 14 Journal of Oncology
Table 1: Outcome results for Phase I trials for patients with advanced colorectal cancer (ACRC).
Overall survival (median) 29.1 weeks
Log-rank P = 0.029 Progression-free survival (median) 8.6 weeks
OS RMH prognostic score 0-1 47.4 weeks 95% CI 41.3–53.6
OS RMH prognostic score 2-3 19.4 weeks 95% CI 11.7–27.1
Prognostic factors Univariate
(log-rank) P =
Multivariate (Cox regression) P =
Age (<62 versus >62 years) 0.653 —
Gender (male) 0.021 0.009
Lung metastases 0.520 —
Liver metastases 0.050 0.508
Previous use of biological agents 0.661 —
Previous local procedures 0.120 —
RMH score 0.029 0.007
Drugs Class Number of trials Number of patients
HDAC/antisense/DNA repair 6 17
Growth factor receptor inhibitor 5 11
Antiangiogenesis 7 15
Cell cycle/apoptosis 3 9
Virus/vaccinia 1 3
Various survival pathways 6 23
RMH:RoyalMarsdenHospital;CI:conﬁdenceinterval;Hdac:histonedeacetylase;Varioussurvivalpathways:includingAkt/PI3kinase/MTOR
pathway.
Table 2: Reasons for referral to Phase I trials? (single choice).
( 1 )N oo t h e ro p t i o n sa v a i l a b l e 3 1 %
(2) Beneﬁt development of new agents 25%
(3) Possibility of clinical beneﬁt for patient 20%
(4) Patients’ or families’ request 10%
(5) Possibility psychological beneﬁt for patient 8%
(6) Know about a speciﬁc ongoing trial 3%
(7) Rather than having end stage disease discussion 3%
Moreover,themajorchallengesofPhaseIclinicaltrialsareto
select those patients who are suitable for trial participation,
to ensure that use of resources is optimized, and that the
burden to patients and their families is minimized. Clearly,
in this situation it is crucial to have a close collaboration
between the Phase I specialist, the referring physician, and
the palliative care team in order to optimise the patient’s
beneﬁt [7, 9, 10].
General eligibility criteria for Phase I trials include life
expectancy greater than 3 months, and this is subject to
clinical evaluation by treating physician and background
experience. Prognostic tools can aid in patient selection and
be incorporated to Phase I clinical trial protocols aiming to
minimise the burden to patients by excluding those who are
inappropriate for trial participation. In addition, palliative
care programs have reduced costs, may be more convenient
for patients, and are considered by many a major component
of cancer care. Palliative care programs improve symptom
Table 3: Which baseline characteristics do you take into account
before referring patients to Phase I treatment? (multiple choice).
(1) Good performance status 93%
(2) Life expectancy longer than 3 months 59%
(3) Normal renal function 56%
(4) Normal liver function 50%
(5) Normal full blood count 40%
(6) Good nutritional status 37%
(7) Life expectancy longer than 6 months 28%
(8) Age 25%
(9) Normal albumin 3%
(10) Ability to travel to Phase I unit 3%
control and the overall quality of life of patients suﬀering
from progressive diseases and oﬀer improved support for
their families [7, 10, 11].
The ability of clinicians to predict survival accurately in
terminally ill cancer patients historically has been unreliable,
and even experienced physicians overestimate survival [12].
Therefore, there was a need for objective parameters to help
predict outcome, and our institution developed a prognostic
score that was prospectively validated and associated with
poor outcome. Low albumin (<35mg/dL), lactate dehydro-
genase (LDH) above the upper limit of normal range and
more than two sites of metastasis were independent negative
prognostic factors deﬁning a risk score able to identify a
group (score 2-3) with poor prognosis [13]. In this context,
we analysed the outcome of a large cohort of ACRC patientsJournal of Oncology 5
Table 4: Issues discussed with patients before referral to Phase I
trials? (single choice).
(1) Aims of Phase I (dose ﬁnding and toxicity) 25%
(2) Possibility of any clinical beneﬁt 23%
(3) Chance of helping future cancer patients 17%
(4) Speciﬁc chance of response to Phase I 15%
(5) Risk of side eﬀects 14%
(6) Speciﬁc drugs that could potentially help 3%
( 7 )O t h e r s(T r a v e lr e q u i r e d) 3 %
who participated in Phase I trials of targeted agents and
conﬁrmed that a high prognostic score was also associated
with poor OS [1].
In our survey oncologists named several parameters as-
sociated with clinical outcome including performance status,
albumin, LDH, and number of metastatic sites. Interestingly,
these factors were also part of our recently developed prog-
nostic score. Other factors such as previous chemotherapy
lines and the presence of liver metastases, which are com-
m o n l yr ega r d e da sn ega ti v ep r o gn o s ti c a t o r s ,w e r em e n ti o n e d
to a lesser extent. None of the ROs regarded gender to be
associated with poor outcome, although our recent ACRC
studyshowedagender-relateddiﬀerenceforsurvival.Gender
disparities and prognosis of colorectal cancer have been de-
scribed and may be associated with hormonal status playing
an important role in the pathogenesis of colorectal cancer
[14].
InestimatingthePFSandOSforACRCpatientsonPhase
I trials, the respondents came close to the outcome data of
the trial. The median estimated PFS and OS were found to
be 8 and 24 weeks respectively, compared with the actual
values of 8.6 and 29.1 weeks. Twenty-ﬁve per cent of ROs
stated that the referral to Phase I trials was made in order
to beneﬁt the development of new compounds. A signiﬁcant
number of ROs having previous experience with early phase
trials combined with the lack of exciting third-line options
for colorectal cancer within the United Kingdom National
Health System may have predisposed these numbers.
In the second part of the present survey, oncologists were
asked to give feedback on whether our clinical outcome data
may impact their future decision-making and subsequently
result in increasing Phase I referrals. Interestingly, nearly
50% of ROs stated they will consider the Phase I prognostic
score for patient selection in the future. Additionally, the
respondents are aiming to increase the time they spend to
discuss diﬀerent aspects of Phase I trials with their patients
and, as a direct result of the provided data, one quarter plan
to increase the number of referrals to our centre.
We are aware that this questionnaire may have limita-
tions, nevertheless the results of this survey have helped us to
better understand on what basis oncologists select patients
for Phase I trials. Moreover, the active exchange of clinical
outcome data with our referring centres could result in im-
provingtheirunderstandingofPhaseItrialsandmayfurther
optimize patient selection. We trust that active engagement
Table 5: Which of these variables do you think aﬀect prognosis of
patients? (multiple choice).
(1) Albumin 97%
(2) Performance status 94%
( 3 )N u m b e ro fm e t a s t a t i cs i t e s 7 8 %
(4) Lines of chemotherapy 62%
(5) Liver metastases 56%
(6) Lactate dehydrogenase (LDH) 46%
(7) Age 37%
(8) Previous biological agents 28%
(9) Lung metastases 25%
(10) Haemoglobin 22%
(11) Previous local procedures (RFA, liver resection) 3%
(12) Gender 0%
of ROs has the potential to improve patient care by minimiz-
ing the referral of poor prognosis patients.
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